Sutro Biopharma names new VP of Clinical Development and promotes Regina Cheng to VP of Finance and Controller
22 May 2020 -

Sutro Biopharma Inc (NASDAQ: STRO), a United States-based clinical-stage drug discovery, development and manufacturing company, announced on Thursday that it has named Craig Berman, MD as its new vice president of Clinical Development and promoted Regina Cheng to vice president of Finance and Controller.

Dr Berman has more than 17 years of experience in drug development, including immuno-oncology. Prior to joining Sutro Biopharma Inc, Berman was VP of Clinical Development at QED Therapeutics. He has also served as senior director of Clinical Development at Halozyme, executive director of Clinical Development at Exelixis and senior director of Clinical Development at Medivation. Berman has also held positions at Sunesis, Novacea, Cell Genesys, and Alza Pharmaceuticals (acquired by Johnson & Johnson).

Cheng has more than 20 years of financial accounting experience and has managed the company's finance and accounting team since 2015. She has held various corporate and divisional controllership management positions at several private and publicly-held technology companies, including CompareNetworks Inc, TeraRecon, Keynote Systems, Sungard Data Systems and Sterling Software.